The Indirect Impact of COVID-19 on Major Clinical Outcomes of People With Parkinson's Disease or Parkinsonism: A Cohort Study

Vignatelli, Luca; Baccari, Flavia; Belotti, Laura Maria Beatrice; Zenesini, Corrado; Baldin, Elisa; Calandra‐Buonaura, Giovanna; Cortelli, Pietro; Descovich, Carlo; Giannini, Giulia; Guarino, Maria; Loddo, Giuseppe; Nassetti, Stefania; Sambati, Luisa; Scaglione, Cesa; Trombetti, Susanna; D’Alessandro, Roberto; Nonino, Francesco

doi:10.3389/fneur.2022.873925

Cited by 6 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These indirect effects of COVID-19 are more confirmed and may be more common and more harmful than the direct effects of viral infections 1,9,10 . The worsening of motor and non-motor symptoms has been attributed to stress, physical inactivity, pharmacodynamic effects, dramatic changes in routine, and social isolation 11,12 . The impact of stress on PD progression has been previously investigated and proven to negatively affect the course of the disease 1,2,4 .…”

Section: Discussionmentioning

confidence: 99%

A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic

Shalash

Helmy

Salama

et al. 2022

npj Parkinsons Dis.

View full text Add to dashboard Cite

Further studies are required to investigate the impact of the COVID-19 pandemic on Parkinson’s disease (PD) progression. This study investigated the motor and non-motor progression of people with PD (PWP) at 6 months during the COVID-19 pandemic compared with that during the pre-pandemic period. Patients were recruited from Ain Shams University Hospitals, Cairo, in the period between April 2019 and December 2020. Fifty patients were included, of whom 17 and 33 patients were followed for 6 months before and during the pandemic, respectively. All patients were assessed at baseline and at 6 months using the MDS-UPDRS, Schwab and England scale (S&E), Hoehn and Yahr scale (H&Y), Berg Balance Scale, Timed Up and Go test (TUG), International Physical Activity Questionnaire, New Freezing of Gait Questionnaire, Non-Motor Symptoms Scale, and Beck Depression Inventory (BDI). Both groups were matched in age, gender, and disease characteristics. Patients followed during the pandemic showed more significant worsening of the total, part I and motor part of MDS-UPDRS, and balance scores (p < 0.001) than those followed during the pre-COVID-19 period. Gait (TUG), balance, and physical activity worsening were significantly correlated with baseline BDI, gait and balance scores, total and part I MDS-UPDRS scores, H&Y, and S&E OFF scores. Gait deterioration (TUG) was correlated with baseline physical activity (r = −0.510, p = 0.002). PWP showed worsening of motor and non-motor symptoms during the COVID-19 pandemic at the 6-month follow-up. Worsening of gait, balance, and physical activity was correlated with baseline motor and physical activity OFF scores.

show abstract

Section: Discussionmentioning

confidence: 99%

A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic

Shalash

Helmy

Salama

et al. 2022

npj Parkinsons Dis.

View full text Add to dashboard Cite

show abstract

“…It is worth mentioning that recent studies have shown that NSCs can fight against COVID-19 [ 26 ]. The susceptibility of the elderly to COVID-19 infection, and the high mortality rate, are strongly associated with indirect clinical outcomes in PD patients [ 102 ]. Therefore, compared with the other above-mentioned compounds, NCS has more advantages in the protective potential of anti-PD.…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective Capability of Narcissoside in 6-OHDA-Exposed Parkinson’s Disease Models through Enhancing the MiR200a/Nrf-2/GSH Axis and Mediating MAPK/Akt Associated Signaling Pathway

Tsai

Liu

et al. 2022

Antioxidants

View full text Add to dashboard Cite

We assessed the antioxidant potential of narcissoside from Sambucus nigra flowers (elderflowers) in Parkinson’s disease models in vitro and in vivo. The results showed that narcissoside lessened the 6-hydroxydopamine (6-OHDA)-induced increase in reactive oxygen species (ROS) and apoptosis in SH-SY5Y cells. In the 6-OHDA-exposed Caenorhabditis elegans model, narcissoside reduced degeneration of dopaminergic neurons and ROS generation, and also improved dopamine-related food-sensitive behavior and shortened lifespan. Moreover, NCS increased total glutathione (GSH) by increasing the expression of the catalytic subunit and modifier subunit of γ-glutamylcysteine ligase in cells and nematodes. Treatment with a GSH inhibitor partially abolished the anti-apoptotic ability of narcissoside. Furthermore, narcissoside diminished the 6-OHDA-induced phosphorylation of JNK and p38, while rising activities of ERK and Akt in resisting apoptosis. The antioxidant response element (ARE)-luciferase reporter activity analysis and electromobility gel shift assay showed that narcissoside promotes the transcriptional activity mediated by Nrf2. Finally, we found that narcissoside augmented the expression of miR200a, a translational inhibitor of the Nrf2 repressor protein Keap1. Downregulation of Nrf2 and miR200a by RNAi and anti-miR200a, respectively, reversed the neuroprotective ability of narcissoside. In summary, narcissoside can enhance the miR200a/Nrf2/GSH antioxidant pathway, alleviate 6-OHDA-induced apoptosis, and has the neuroprotective potential.

show abstract

“…Multiple studies showed that essential health services for chronic noncommunicable diseases were reduced or disrupted during the COVID-19 pandemic, potentially leading to a worse outcome or higher risk of death [11,12]. The comparison shows a dramatic increase in emergency admissions.…”

Section: Reports Of Neurological Manifestations Of Omicron Infectionmentioning

confidence: 99%

Neurological complications during the Omicron COVID‐19 wave in China: A cohort study

Lu,

Chen,

Wang

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe aim was to investigate the neurological complications associated with coronavirus disease 19 (COVID‐19) during the 2022 Omicron wave.Methods and analysisThe medical records of a cohort of people admitted to neurological wards of three participating tertiary centres in Sichuan from 12 December 2022 to 12 January 2023 were reviewed. Demographics and clinical data were obtained and analysed with an interest in COVID‐19‐related new‐onset or worse neurological symptoms. The current data were also compared in two centres with similar data from the same period 12 months earlier.ResultsIn all, 790 people were enrolled, of whom 436 were positive for COVID‐19. Ninety‐nine had new onset COVID‐related neurological problems, or their known neurological condition deteriorated during the wave. There was a significant difference in demographics from the findings amongst admissions 12 months earlier as there was an increase in the average age, the incidence of encephalitis and encephalopathy, and mortality rates. One hundred and one received COVID‐specific antivirals, intravenous glucocorticoids and intravenous immunoglobulin therapy. No differences were seen between these and those who did not use them.ConclusionNew‐onset neurological conditions, particularly encephalitis and encephalopathy, increased significantly during this period. Deterioration of existing neurological conditions, such as seizure exacerbation, was also observed. A large‐scale treatment trial of people with COVID‐19 infection presenting with neurological disorders is still needed.

show abstract

The Indirect Impact of COVID-19 on Major Clinical Outcomes of People With Parkinson's Disease or Parkinsonism: A Cohort Study

Cited by 6 publications

References 45 publications

A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic

A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic

Neuroprotective Capability of Narcissoside in 6-OHDA-Exposed Parkinson’s Disease Models through Enhancing the MiR200a/Nrf-2/GSH Axis and Mediating MAPK/Akt Associated Signaling Pathway

Neurological complications during the Omicron COVID‐19 wave in China: A cohort study

Contact Info

Product

Resources

About